A Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome

Treatment with decoctions of traditional Chinese medicines such as cinnamon twigs has solved the problems of preventing and treating OHSS, reduced the incidence and symptoms of OHSS, improved the quality of life of patients, and has fewer ingredients, making it cost-effective.

CN118178595BActive Publication Date: 2024-11-26PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410247538.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-05
Publication Date
2024-11-26
Estimated Expiration
2044-03-05

AI Technical Summary

Technical Problem

There is a lack of effective traditional Chinese medicine treatment options for the prevention and treatment of ovarian hyperstimulation syndrome (OHSS) in the current technology. Moreover, existing options often require the use of Western medicine in combination or have too many ingredients, and the treatment cycle and duration are unclear.

Method used

A traditional Chinese medicine composition is provided, consisting of cinnamon twig, poria cocos, atractylodes macrocephala, winter melon peel, areca peel, polyporus umbellatus, tangerine peel and ginger. The decoction is prepared by boiling and taken twice a day, 200ml each time, one hour after meals, for a total of 5 days, for the prevention and treatment of OHSS.

Benefits of technology

It significantly reduces the incidence and symptoms of OHSS, such as abdominal distension and vomiting, improves patients' quality of life, is cost-effective, and has good clinical compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GHA0000005738150000051
    Figure GHA0000005738150000051
  • Figure GHA0000005738150000061
    Figure GHA0000005738150000061
  • Figure GHA0000005738150000071
    Figure GHA0000005738150000071
Patent Text Reader

Abstract

The invention discloses a Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome. The Chinese medicine composition provided by the invention comprises the following components: 1-20 weight parts of cinnamon twig, 6-50 weight parts of Poria cocos, 5-40 weight parts of Atractylodes macrocephala, 5-50 weight parts of wax gourd peel, 5-50 weight parts of dried tangerine peel, 1-20 weight parts of Polyporus umbellatus, 1-20 weight parts of dried tangerine peel, and 1-20 weight parts of ginger. The Chinese medicine composition provided by the invention can achieve the effect of preventing and treating ovarian hyperstimulation syndrome in traditional Chinese medicine by taking it in the early stage, and the composition of medicinal taste is less, the clinical compliance is good, and the cost performance is high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome. Background Art

[0002] Ovarian hyperstimulation syndrome (OHSS) is a complication of ovulation induction caused by the action of exogenous gonadotropin (Gn), which is mainly manifested by systemic reactions such as ovarian enlargement, ascites, oliguria, and hemoconcentration. OHSS is the most important iatrogenic complication of controlled ovulation induction, with a total incidence of 3% to 10% in all assisted reproductive treatment cycles, and a severe OHSS incidence of 0.1% to 2.0%. The specific pathogenesis of OHSS is still unclear, and neovascularization and increased vascular permeability are the main pathophysiological changes. Ovulation induction leads to a significant increase in the secretion of ovarian vasoactive substances such as vascular endothelial growth factor (VEGF), which increases capillary permeability and allows protein-rich body fluids to penetrate from the blood vessels into the third space, leading to ascites, pleural effusion, pericardial effusion, and even systemic edema, followed by abdominal distension, abdominal pain, hemoconcentration, hypovolemia, oliguria, liver and kidney dysfunction, and in severe cases, thrombosis, acute respiratory distress syndrome, renal failure, and even life-threatening. Therefore, early prevention of OHSS is crucial.

[0003] There are two key nodes in the prevention and treatment of OHSS. The first is to identify potential high-risk groups before ovulation induction, and reduce the occurrence of OHSS by choosing a mild ovulation induction plan, reducing the dosage and duration of ovulation induction drugs, etc. The other node is in the late ovulation induction and on the day of egg retrieval. Commonly used drugs for preventing OHSS include dopamine receptor agonists, metformin, aspirin, calcium supplements, albumin and hydroxyethyl starch, etc., but the efficacy of all these drugs is not completely certain, and there are potential adverse reactions such as dizziness, drowsiness, nausea, vomiting, diarrhea, abdominal pain, and loss of appetite.

[0004] Traditional Chinese medicine does not have a clear record of OHSS, but combined with the patient's symptom characteristics and clinical manifestations, it can be classified into the categories of "swelling" and "edema". In the process of ovulation induction of modern assisted reproductive technology, large doses of gonadotropin stimulate the ovaries. Traditional Chinese medicine believes that this process will consume kidney essence, damage the yin and yang of the kidney, form spleen and kidney deficiency, and cause the disorder of water flow in the triple energizer and the disorder of qi movement, forming the syndrome of deficiency in the root and excess in the superficial. "The kidney stores essence and controls water", the function of kidney qi transpiration and warming is not used, and the bladder is unable to gasify, which will cause oliguria or anuria; "The spleen is responsible for transportation and transformation, and is responsible for ascending the clear", if the spleen qi and spleen yang are weak, the water and moisture cannot be transformed, and the abdominal distension, nausea, poor appetite, and even ascites can be seen.

[0005] Some TCM treatment plans for OHSS have been proposed in the prior art, but there are some problems. For example, the actual treatment process must be combined with Western medicine synergistic treatment, and Western medicine treatment is based on traditional Chinese medicine as a supplement; or, the traditional Chinese medicine compound has too many ingredients, and the treatment cycle and the time of traditional Chinese medicine intervention are unclear. Summary of the invention

[0006] The purpose of the present invention is to provide a traditional Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome. By taking the composition at an early stage, the effect of preventing and treating ovarian hyperstimulation syndrome by traditional Chinese medicine can be achieved, and the composition has fewer medicinal flavors, good clinical compliance, and high cost performance.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a traditional Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome, which is made from the following traditional Chinese medicine raw materials: 1-20 parts by weight of cinnamon twig, 6-50 parts by weight of Poria cocos, 5-40 parts by weight of Atractylodes macrocephala, 5-50 parts by weight of wax gourd peel, 5-50 parts by weight of dried tangerine peel, 1-20 parts by weight of Poria cocos, 1-20 parts by weight of dried tangerine peel, and 1-20 parts by weight of ginger.

[0009] Preferably, the Chinese medicine composition is made of the following Chinese medicine raw materials: 6-10 parts by weight of cinnamon twig, 15-30 parts by weight of Poria cocos, 10-20 parts by weight of Atractylodes macrocephala, 10-30 parts by weight of wax gourd peel, 10-30 parts by weight of dried tangerine peel, 5-10 parts by weight of Polyporus umbellatus, 5-10 parts by weight of dried tangerine peel, and 5-10 parts by weight of ginger.

[0010] In a second aspect, the present invention further provides a traditional Chinese medicine extract for preventing and treating ovarian hyperstimulation syndrome, which is extracted from the following traditional Chinese medicine raw materials: 1-20 weight parts of cinnamon twig, 6-50 weight parts of Poria cocos, 5-40 weight parts of Atractylodes macrocephala, 5-50 weight parts of wax gourd peel, 5-50 weight parts of dried tangerine peel, 1-20 weight parts of Polyporus umbellatus, 1-20 weight parts of dried tangerine peel, and 1-20 weight parts of ginger.

[0011] Preferably, the Chinese medicine extract is obtained by extracting from the following Chinese medicine raw materials: 6-10 weight parts of cinnamon twig, 15-30 weight parts of Poria cocos, 10-20 weight parts of Atractylodes macrocephala, 10-30 weight parts of wax gourd peel, 10-30 weight parts of dried tangerine peel, 5-10 weight parts of Polyporus umbellatus, 5-10 weight parts of dried tangerine peel, and 5-10 weight parts of ginger.

[0012] The extraction is carried out according to the following operation: soak the Chinese medicinal raw materials in water with a volume 2-3 times the original volume, boil them with high heat, and then simmer them with low heat until the volume of the medicinal liquid is reduced to 1 / 3-1 / 2 of the original volume.

[0013] In a third aspect, the present invention further provides a Chinese medicine preparation for preventing and treating ovarian hyperstimulation syndrome, comprising the above-mentioned Chinese medicine composition or the above-mentioned Chinese medicine extract.

[0014] The dosage forms of the Chinese medicine preparation include: decoction, tablet, powder, granule or capsule.

[0015] In a fourth aspect, the present invention further provides the use of the Chinese medicine composition, Chinese medicine extract or Chinese medicine preparation in the preparation of a drug for preventing and treating ovarian hyperstimulation syndrome.

[0016] The prevention includes, but is not limited to, reducing the incidence of severe ovarian hyperstimulation syndrome.

[0017] The treatment includes but is not limited to reducing the patient's discomfort symptoms after follicle collection; the discomfort symptoms include but are not limited to abdominal distension and vomiting.

[0018] According to one embodiment of the present invention, the Chinese medicine preparation is a decoction, which can be prepared according to a conventional decoction method; the administration method is: starting to take the medicine one day after egg retrieval, one dose per day, taken twice a day, morning and evening, 200 ml each time, taken one hour after a meal, for a total of 5 days.

[0019] The effects of the Chinese medicinal raw materials used in the present invention are as follows:

[0020] Cinnamon twig: pungent, sweet, warm, enters the lung, heart, and bladder meridians. It induces sweating and relieves muscle pain, warms and dredges the meridians, and helps yang and transforms qi.

[0021] Poria: sweet, light, neutral, enters the lung, heart, spleen, and kidney meridians. It has diuretic and dampness-removing effects, strengthens the spleen, and calms the mind.

[0022] Atractylodes macrocephala: bitter, sweet, warm, enters the spleen and stomach meridians. Strengthens the spleen and replenishes qi, dries dampness and promotes diuresis, consolidates the exterior and stops sweating.

[0023] Winter melon peel: sweet, cool, enters the small intestine and spleen meridians. Diuretic and detumescent, clears away heat and relieves summer heat.

[0024] Radix Phellodendri: pungent, slightly warm, enters the spleen, stomach, large intestine, and small intestine meridians. Promotes qi and relieves fullness, promotes water circulation and reduces swelling.

[0025] Poria: sweet and mild in taste, neutral in nature, enters the kidney and spleen meridians. Enters the kidney and bladder meridians. It has the functions of diuresis, diuresis, and relieving stranguria and turbidity.

[0026] Tangerine peel: bitter, pungent, warm. Enters the spleen and liver meridians. Regulates qi and strengthens the spleen, dries dampness and resolves phlegm.

[0027] Ginger: spicy, slightly warm in nature. Enters the lung, spleen, and stomach meridians. Relieves cold, warms the middle and stops vomiting, warms the lungs and stops coughing, and detoxifies.

[0028] In the process of ovulation induction in modern assisted reproductive technology, a large dose of gonadotropin is needed to stimulate the ovaries. Traditional Chinese medicine believes that this process will consume kidney essence, damage yang qi, cause spleen deficiency and dampness, and cause the disorder of water flow in the triple energizer and the disorder of qi movement, forming the syndrome of deficiency in the root and excess in the superficial. "The kidney stores essence and controls water", if the function of kidney qi transpiration and warming is not used, and the bladder is unable to transform qi, then oliguria or anuria will occur; "The spleen controls transportation and transformation, and controls the ascending of clearness", if the spleen qi and spleen yang are weak, the water and dampness cannot be transformed, and abdominal distension, nausea, poor appetite, and even ascites can be seen.

[0029] The Chinese medicine composition used in the present invention is based on Wulingsan combined with Wupiyin as a basic formula with additions and subtractions, wherein cinnamon twig is the main drug, which has the effect of warming yang and transforming dampness, tuckahoe and atractylodes are the assistant drugs, which have the effect of invigorating the spleen and transforming dampness, wax gourd peel, dried tangerine peel and umbellatus are the adjuvant drugs, which have the effect of promoting diuresis and removing dampness, tangerine peel can regulate qi and harmonize the stomach, and ginger warms the middle and stops vomiting, which are the guiding drugs, and together they have the function of harmonizing the spleen and stomach. The whole formula has the effects of warming yang and invigorating the spleen, promoting diuresis and removing dampness, can alleviate the clinical symptoms of OHSS (abdominal distension, vomiting, etc.), reduce the E2 level after egg retrieval, and shorten the course of the disease.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] The present invention can fill the gap of the current medical field in the lack of effective treatment options for OHSS. The traditional Chinese medicine composition has fewer medicinal flavors, can effectively prevent and treat OHSS, can alleviate the clinical symptoms of OHSS, significantly improve the quality of life of patients, and has good clinical compliance and high cost performance. DETAILED DESCRIPTION

[0032] The present invention will be further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments.

[0033] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0034] Unless otherwise specified, the reagents, materials, instruments, etc. used in the following examples can be obtained from commercial sources.

[0035] Example 1

[0036] Prescription: 6g of cinnamon twig, 15g of Poria cocos, 10g of Atractylodes macrocephala, 10g of wax gourd peel, 10g of dried tangerine peel, 5g of Polyporus umbellatus, 5g of dried tangerine peel, and 5g of ginger.

[0037] The above-mentioned Chinese medicine composition is prepared according to the following operation: soak the above-mentioned Chinese medicine components in 1000ml of water for 2h, then boil it with high heat, and then simmer it with low heat until the solution volume is 400ml. Take it twice a day, morning and evening, 200ml each time.

[0038] Example 2

[0039] Prescription: 10g of cinnamon twig, 30g of Poria cocos, 20g of Atractylodes macrocephala, 30g of wax gourd peel, 30g of dried tangerine peel, 10g of Poria cocos, 10g of dried tangerine peel, and 10g of ginger.

[0040] The above-mentioned Chinese medicine composition is prepared according to the following operation: soak each Chinese medicine component in 1500ml of water for 2h, then boil it with high heat, and then simmer it with low heat until the solution volume is 400ml. Take it twice a day, morning and evening, 200ml each time.

[0041] Example 3

[0042] Prescription: 8g of cinnamon twig, 23g of Poria cocos, 15g of Atractylodes macrocephala, 15g of wax gourd peel, 20g of dried tangerine peel, 8g of Polyporus umbellatus, 8g of dried tangerine peel, and 8g of ginger.

[0043] The above-mentioned Chinese medicine composition is prepared according to the following operation: soak each Chinese medicine component in 1500ml of water for 2h, then boil it with high heat, and then simmer it with low heat until the solution volume is 400ml. Take it twice a day, morning and evening, 200ml each time.

[0044] Example 4

[0045] Prescription: 10g of cinnamon twig, 30g of Poria cocos, 15g of Atractylodes macrocephala, 20g of wax gourd peel, 15g of dried tangerine peel, 10g of Poria cocos, 10g of dried tangerine peel, and 10g of ginger.

[0046] The above-mentioned Chinese medicine composition is prepared according to the following operation: soak each Chinese medicine component in 1500ml of water for 2h, then boil it with high heat, and then simmer it with low heat until the solution volume is 400ml. Take it twice a day, morning and evening, 200ml each time.

[0047] Experimental Example 1

[0048] To verify the clinical effect of the Chinese medicine composition, a single-center prospective cohort study was conducted in the Reproductive Center of our hospital to verify the clinical efficacy of the Chinese medicine composition.

[0049] 1. Grouping and administration method:

[0050] Between March 2022 and March 2023, a total of 120 patients at high risk of ovarian hyperstimulation syndrome (OHSS) after in vitro fertilization-embryo transfer (IVF-ET) completed the study (i.e., resumed menstruation), and all patients signed informed consent.

[0051] The 120 patients were divided into 2 groups:

[0052] Lifestyle counseling intervention (LC) group: 60 people, patients were intervened according to the uniformly formulated "Daily Diet Plan for Patients with Ovarian Hyperstimulation".

[0053] Chinese medicine treatment + LC group: 60 people, on the basis of lifestyle counseling, according to the Chinese medicine composition formula of Example 2, mechanical decoction; start taking the medicine 1 day after egg retrieval, take 200 ml each time, take once in the morning and evening, take once after meal, for a total of 5 days.

[0054] Table 1 Daily diet plan for patients with ovarian hyperstimulation syndrome

[0055]

[0056] 2. The criteria for judging the efficacy are as follows:

[0057] Main outcome measures: The incidence of OHSS and the discomfort symptoms of patients after ovarian follicle collection, including abdominal distension, abdominal pain, diarrhea, nausea, vomiting, decreased urine output, and dyspnea.

[0058] Secondary outcome measures: estradiol levels after follicle collection, changes in ovarian morphology, and resumption of menstruation.

[0059] 3. Collect the following information from the subjects on the day of egg retrieval:

[0060] (1) Basic demographic information of the patient, including age, height, weight, and years of infertility;

[0061] (2) IVF information such as ovulation induction regimen, indication for fertility assistance, Gn dosage and number of days, E2 level on HCG day and number of eggs obtained, and ovarian size;

[0062] (3) measuring the patient's abdominal circumference on the day of oocyte retrieval;

[0063] (4) Evaluation of Traditional Chinese Medicine Syndrome Scale.

[0064] 4. Collect the following information from the subjects 6 days after egg retrieval:

[0065] (1) Symptoms of OHSS (abdominal distension, diarrhea, dyspnea, oliguria, and poor appetite);

[0066] (2) Adverse reactions during taking Chinese medicine;

[0067] (3) Physical examination: weight, abdominal circumference, abdominal examination, and chest examination;

[0068] (4) Gynecological ultrasound: size of bilateral ovaries, uterine rectal fossa, and pelvic and abdominal effusion;

[0069] (5) Routine blood test: serum E2 and P levels;

[0070] (6) For patients with severe symptoms such as abdominal pain, abdominal distension, oliguria, chest tightness and shortness of breath, blood coagulation test, urine routine, liver and kidney function, and chest ultrasound should be increased;

[0071] (7) Traditional Chinese Medicine Syndrome Scale.

[0072] 5. Research Results

[0073] The clinical trial results are shown in the table below.

[0074] Table 2 Baseline characteristics of subjects in Experimental Example 1

[0075]

[0076]

[0077] Abbreviations: E2, estradiol; GnRH, gonadotropin-releasing hormone; HCG, human chorionic gonadotropin; IUI, intrauterine insemination; IVF, in vitro fertilization; LH, luteinizing hormone; P, progesterone; PCOS, polycystic ovary syndrome; OPU, oocyte retrieval.

[0078] Table 3 Changes in patient indicators before and after intervention in Experimental Example 1

[0079]

[0080] Abbreviations: LOV, Left Ovary; ROV, Right Ovary.

[0081] The test results of Experimental Example 1 show that:

[0082] (1) Compared with the LC group, the TCM treatment + LC group had a lower incidence of abdominal distension (RR: 0.86; 95% CI: 0.76-0.97; p = 0.015), which was statistically significant (p < 0.05); a shorter duration of abdominal distension, which was statistically significant (p < 0.01); a lower incidence of vomiting (RR: 0.38; 95% CI: 0.15-1.01; p = 0.041), which was statistically significant (p < 0.05); and fewer vomiting times (p = 0.025), which was statistically significant (p < 0.05). This shows that the TCM composition provided by the present invention can significantly reduce the incidence of abdominal distension, significantly shorten the duration of abdominal distension, significantly reduce the incidence of vomiting, and significantly reduce the number of vomiting.

[0083] In addition, during the follow-up period, two patients in the LC group sought emergency treatment, while only one patient in the TCM treatment + LC group sought emergency treatment, indicating that the TCM composition provided by the present invention can reduce the number of emergency treatment situations.

[0084] (2) In terms of secondary outcome indicators, compared with the LC group, the TCM treatment + LC group had a greater decrease in estradiol levels after follicle collection, which was statistically significant (p<0.05); while with menstrual recovery as the endpoint, there was no difference between the two groups in the number of days from ovulation to menstrual recovery (p=0.314). This shows that the TCM composition provided by the present invention can significantly reduce estradiol levels after follicle collection.

[0085] Experimental Example 2

[0086] Between January and March 2024, 48 patients at high risk of ovarian hyperstimulation syndrome (OHSS) after in vitro fertilization-embryo transfer (IVF-ET) were enrolled (25 in the experimental group and 23 in the control group).

[0087] The experimental group was treated with the Chinese medicine composition obtained in Example 4.

[0088] The control group was treated with Chinese medicine for invigorating the spleen and promoting diuresis (15g of Atractylodes macrocephala, 15g of Poria cocos, 15g of Polyporus umbellatus, 12g of Alisma orientalis, 6g of Amomum villosum, 6g of ginger, 9g of cinnamon twig, and 6g of dried tangerine peel); this prescription also used the drugs of Wuling Powder combined with Wupi Yin, but the therapeutic idea was different from that of the drugs of the present invention, the monarch, minister, adjuvant and envoy were different, and the overall use of drugs was different.

[0089] During the medication period, both groups of patients received lifestyle and dietary guidance, and the occurrence, severity and adverse reactions of OHSS-related clinical symptoms after medication were evaluated.

[0090] Table 4 Baseline characteristics of subjects in Experimental Example 2

[0091]

[0092]

[0093] Table 5 Clinical symptoms of OHSS in Experimental Example 2

[0094] Clinical symptoms of OHSS Experimental Group Control group RR (95% CI) t <![CDATA[X 2 ]]> p value Abdominal distension, n (%) 18(72.00) 23(100.00) 0.72(0.564-0.919) 7.540 0.007 Abdominal pain, n (%) 21(84.00) 23(100.00) 0.84(0.708-0.997) 4.015 0.065 Diarrhea, n (%) 7(28.00) 9(39.13) 0.72(0.319-1.607) 0.668 0.414 Nausea, n (%) 5(20.00) 6(26.09) 0.77(0.270-2.176) 0.251 0.616 Vomiting, n (%) 1(4.00) 2(8.70) 0.46(0.045-4.741) 0.451 0.468 Decreased urine volume, n (%) 5(20.00) 9(39.13) 0.51(0.201-1.302) 2.122 0.145 Dyspnea, n (%) 1(4.00) 3(13.04) 0.31(0.034-2.743) 1.283 0.273

[0095] The test results show that: the baseline comparison between the two groups, as shown in Table 5, the test group has more eggs obtained, and the maximum diameter of the right ovary before OPU is larger, that is, the test group has a higher risk of OHSS. However, after treatment with the Chinese medicine composition provided by the present invention, the clinical symptoms related to OHSS are shown in Table 6. Compared with the control group, the test group has a lower incidence of abdominal distension (RR: 0.72; 95% CI: 0.564-0.919; p = 0.007), which is statistically significant (p < 0.05); due to the small sample size, other clinical symptoms did not show statistical differences.

[0096] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A Chinese medicine composition for preventing and treating ovarian hyperstimulation syndrome, which is made from the following Chinese medicine raw materials: 10 parts by weight of cinnamon twig, 30 parts by weight of Poria cocos, 15 parts by weight of Atractylodes macrocephala, 20 parts by weight of wax gourd peel, 15 parts by weight of dried tangerine peel, 10 parts by weight of Polyporus umbellatus, 10 parts by weight of dried tangerine peel, and 10 parts by weight of ginger.

2. A Chinese medicine extract for preventing and treating ovarian hyperstimulation syndrome, which is extracted from the following Chinese medicine raw materials: 10 parts by weight of cinnamon twig, 30 parts by weight of Poria cocos, 15 parts by weight of Atractylodes macrocephala, 20 parts by weight of wax gourd peel, 15 parts by weight of dried tangerine peel, 10 parts by weight of Poria cocos, 10 parts by weight of dried tangerine peel, and 10 parts by weight of ginger.

3. The Chinese medicinal extract for preventing and treating ovarian hyperstimulation syndrome according to claim 2, characterized in that: The extraction is carried out according to the following operation: soak the Chinese medicinal raw materials in water with a volume 2-3 times the original volume, boil them with high heat, and then simmer them with low heat until the volume of the medicinal liquid is reduced to 1 / 3-1 / 2 of the original volume.

4. A Chinese medicine preparation for preventing and treating ovarian hyperstimulation syndrome, comprising the Chinese medicine composition according to claim 1, or the Chinese medicine extract according to claim 2 or 3.

5. The Chinese medicine preparation for preventing and treating ovarian hyperstimulation syndrome according to claim 4, characterized in that: The dosage forms of the Chinese medicine preparation include: decoction, tablet, powder, granule or capsule.

6. Use of the Chinese medicine composition according to claim 1, the Chinese medicine extract according to claim 2 or 3, or the Chinese medicine preparation according to claim 4 or 5 in the preparation of a drug for preventing and treating ovarian hyperstimulation syndrome.

7. The use according to claim 6, characterized in that: The prevention includes but is not limited to reducing the incidence of severe ovarian hyperstimulation syndrome; The treatment includes but is not limited to reducing the patient's discomfort symptoms after follicle collection; the discomfort symptoms include but are not limited to abdominal distension and vomiting.